These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The influence of the pharmaceutical industry in medicine. Jelinek GA; Neate SL J Law Med; 2009 Oct; 17(2):216-23. PubMed ID: 19998591 [TBL] [Abstract][Full Text] [Related]
3. Interactions with the investment industry: practical and ethical implications. American Society of Clinical Oncology J Clin Oncol; 2007 Jan; 25(3):338-40. PubMed ID: 17235050 [No Abstract] [Full Text] [Related]
4. The role of pharmaceutical companies in sponsored research. Novack GD Ophthalmology; 2007 Jun; 114(6):1037-8. PubMed ID: 17544773 [No Abstract] [Full Text] [Related]
5. [Increased commercial financing of national Medical Product Agencies within the EU]. Ramel B Lakartidningen; 2003 Jan; 100(5):338-9. PubMed ID: 12607381 [No Abstract] [Full Text] [Related]
6. Current trends in the clinical development of peptide therapeutics. Saladin PM; Zhang BD; Reichert JM IDrugs; 2009 Dec; 12(12):779-84. PubMed ID: 19943221 [TBL] [Abstract][Full Text] [Related]
7. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Innovations in care that advance Alzheimer's disease drug development. Foster NL; Andersen TC; Zamrini EY Alzheimers Dement; 2009 Mar; 5(2):159-62. PubMed ID: 19328451 [TBL] [Abstract][Full Text] [Related]
8. Time for the medical profession to act: new policies needed now on interactions between pharmaceutical companies and physicians. Greenland P Arch Intern Med; 2009 May; 169(9):829-31. PubMed ID: 19433693 [No Abstract] [Full Text] [Related]
9. [Drug evaluation: new requirements and perspectives]. Addis A; Rocchi F Recenti Prog Med; 2006 Nov; 97(11):618-25. PubMed ID: 17252718 [TBL] [Abstract][Full Text] [Related]
10. Scientific harassment by pharmaceutical companies: time to stop. Hailey D CMAJ; 2000 Jan; 162(2):212-3. PubMed ID: 10674057 [No Abstract] [Full Text] [Related]
11. [Physicians' participation in clinical drug trials]. Nielsen OH; Ainsworth M Ugeskr Laeger; 2003 Apr; 165(16):1639. PubMed ID: 12756815 [No Abstract] [Full Text] [Related]
12. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
13. Biased articles. Friedman JH Med Health R I; 2009 Mar; 92(3):70. PubMed ID: 19385378 [No Abstract] [Full Text] [Related]
14. [Standards for commercialization of medications in the European Union]. Benzi G Cardiologia; 1999 Dec; 44 Suppl 1(Pt 1):33-7. PubMed ID: 12497878 [No Abstract] [Full Text] [Related]
15. The state of innovation in drug development. Kola I Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690 [TBL] [Abstract][Full Text] [Related]
16. Perspectives on drug withdrawals. Williams R CMAJ; 2005 Jul; 173(2):129. PubMed ID: 16027417 [No Abstract] [Full Text] [Related]
17. [The physician in the pharmaceutical industry]. Lopes ID; Gomes MV; Branco JC Acta Med Port; 1993 Jul; 6(7):361-5. PubMed ID: 8379357 [TBL] [Abstract][Full Text] [Related]
18. [We--the incorruptible?]. Stavdal A; Fosse A Tidsskr Nor Laegeforen; 2004 May; 124(10):1370. PubMed ID: 15195170 [No Abstract] [Full Text] [Related]
19. Medicine and industry: a necessary but conflicted relationship. Fisher MA Perspect Biol Med; 2007; 50(1):1-6. PubMed ID: 17259671 [TBL] [Abstract][Full Text] [Related]
20. Patient awareness and concern regarding pharmaceutical manufacturer interactions with doctors. Edwards D; Ballantyne A Intern Med J; 2009 Mar; 39(3):191-6. PubMed ID: 19383067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]